Clinical Trials · NCT02894398
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- iOMEDICO AG
- Enrollment
- 388
- Start date
- Sep 2016
- Locations
- 70 sites, Germany
- Primary endpoint
- Clinical Benefit Rate (CBR)